atopic dermatitis

Dupixent's already a blockbuster, but there's much more to come: Sanofi exec
Dupixent's already a blockbuster, but there's much more to come: Sanofi exec
Fierce Pharma
Sanofi
Dupixent
atopic dermatitis
Flag link:
Trials of Novartis' Dupixent rival bet scrapped by MorphoSys, Galapagos
Trials of Novartis' Dupixent rival bet scrapped by MorphoSys, Galapagos
Fierce Biotech
MorphoSys
Galapagos
Novartis
MOR106
atopic dermatitis
Dupixent
Sanofi
Flag link:
RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193
RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193
Pharmaceutical Business Review
RAPT Therapeutics
RPT193
allergies
atopic dermatitis
clinical trials
Flag link:
Pfizer posts detailed phase 3 data on its Dupixent rival
Pfizer posts detailed phase 3 data on its Dupixent rival
Fierce Biotech
Pfizer
clinical trials
atopic dermatitis
abrocitinib
Dupixent
Sanofi
Regeneron
Flag link:
Pfizer’s Abrocitinib yields positive results in phase 3 moderate to severe AD trial
Pfizer’s Abrocitinib yields positive results in phase 3 moderate to severe AD trial
Pharmaceutical Business Review
Pfizer
clinical trials
PF-04965842
atopic dermatitis
Flag link:
Why Dermira Stock Jumped Again Today
Why Dermira Stock Jumped Again Today
Motley Fool
Demira
lebrikizumab
atopic dermatitis
Flag link:
Microbiome Report for Week Ending 3/9/19
Microbiome Report for Week Ending 3/9/19
CP Wire
microbiome
Synlogic
AOBiome
AbbVie
Infant Bacterial Therapeutics
IBD
atopic dermatitis
Flag link:
FDA approves Dupixent for atopic dermatitis in adolescents
FDA approves Dupixent for atopic dermatitis in adolescents
BioCentury
Dupixent
Regeneron
Sanofi
FDA
atopic dermatitis
Flag link:
Lilly and Incyte's Olumiant Hits the Mark in Two Phase III Atopic Dermatitis Trials
Lilly and Incyte's Olumiant Hits the Mark in Two Phase III Atopic Dermatitis Trials
BioSpace
Eli Lilly
Incyte
olumiant
atopic dermatitis
clinical trials
Flag link:
Microbiome Report for Week Ending 12/1/18
Microbiome Report for Week Ending 12/1/18
CP Wire
microbiome
Evelo Biosciences
Kaleido Biosciences
Vedanta Biosciences
psoriasis
atopic dermatitis
IBD
Flag link:
Microbiome Report for Week Ending 12/1/18
Evelo Biosciences
Kaleido Biosciences
Vedanta Biosciences
psoriasis
atopic dermatitis
IBD
Flag link:
Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster star Dupixent
Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster star Dupixent
Endpoints
Sanofi
Regeneron
Dupixent
atopic dermatitis
Flag link:
Sanofi unveils eczema drug data, as regulators mull label expansion
Sanofi unveils eczema drug data, as regulators mull label expansion
Pharmaforum
Sanofi
Dupixent
dupilumab
eczema
atopic dermatitis
Flag link:
After back-to-back trial flops, Realm slashes its staff, halts research work and ponders a fire sale
After back-to-back trial flops, Realm slashes its staff, halts research work and ponders a fire sale
Endpoints
Realm Therapeutics
atopic dermatitis
clinical trials
layoffs
Flag link:
Realm Craters As Another Phase II Trial Fails to Reach Endpoints
Realm Craters As Another Phase II Trial Fails to Reach Endpoints
BioSpace
Realm Therapeutics
atopic dermatitis
clinical trials
PR022
Flag link:
Novartis to Pay as Much as $1 Billion for Rights to Skin Drug
Novartis to Pay as Much as $1 Billion for Rights to Skin Drug
Yahoo/Bloomberg
Novartis
Galapagos
MorphoSys
MOR106
atopic dermatitis
Flag link:
Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug
Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug
Fierce Biotech
GSK
Dermavant
Roivant
CSO
tapinarof
psoriasis
atopic dermatitis
Flag link:
Sanofi's Dupixent scores NICE recommendation after price cut
Sanofi's Dupixent scores NICE recommendation after price cut
Fierce Pharma
Sanofi
NICE
atopic dermatitis
Dupixent
Flag link:
Great data! Huge potential! (Too bad it failed the primary endpoint)
Great data! Huge potential! (Too bad it failed the primary endpoint)
Endpoints
Vanda Pharmaceuticals
tradipitant
atopic dermatitis
Flag link:
AbbVie preps JAK atopic dermatitis candidate for phase 3
AbbVie preps JAK atopic dermatitis candidate for phase 3
Fierce Biotech
AbbVie
JAK inhibitors
clinical trials
atopic dermatitis
Upadacitinib
Sanofi
Regeneron
Dupixent
Flag link:

Pages